JMP keeps Oscient at strong buy

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a strong buy after the company reported a third-quarter loss per share of $0.20, meeting the Street estimate of a $0.20 loss and beating JMP's estimate of a $0.26 loss. Factive sales of $4.0 million were higher than the analyst's $3.2 million estimate. Antara sales of $4.3 million were also higher than Cutler's expectation of $3.6 million estimate. Shares of the Waltham, Mass., biopharmaceutical company were down 1 cent, or 0.94%, at $1.05. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.